{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T20:53:30Z","timestamp":1786136010042,"version":"build-2736575974"},"reference-count":48,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"32","license":[{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Chengdu Traditional Chinese Medicine University","award":["XJ2023009701"],"award-info":[{"award-number":["XJ2023009701"]}]},{"name":"Chengdu Traditional Chinese Medicine University","award":["JGJD202435"],"award-info":[{"award-number":["JGJD202435"]}]},{"name":"Deyang Science and Technology Bureau","award":["2024SZY003"],"award-info":[{"award-number":["2024SZY003"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8,7]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      This study aimed to investigate whether interleukin-6 (IL-6) receptor inhibitors affect cerebrospinal fluid (CSF) metabolites in type 2 diabetes (T2D) patients. The initial phase employed drug-targeted Mendelian randomization to investigate the association between IL-6 receptor inhibitors and T2D across diverse populations. Subsequently, variables related to T2D were utilized as mediators in the relationship between IL-6 receptor inhibitors and CSF metabolites. Finally, the mediating effect of T2D was evaluated using mediation analysis. In the European cohort, the use of IL-6 receptor inhibitors was associated with a 25.3% reduction in the risk of T2D, as indicated by an odds ratio of 0.747 with a 95% confidence interval ranging from 0.556 to 0.938 (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .003). In the East Asian cohort, IL-6 receptor inhibitors were associated with a 1.188-fold increase in the risk of elevated fasting insulin levels, with an odds ratio of 1.188 and a 95% confidence interval of 1.034 to 1.343 (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .029). Mediation analysis revealed that IL-6 receptor inhibitors significantly elevated the levels of galacto-glycero-lipid (GG) in CSF, with 3.06% of the effect attributable to the reduced risk of T2D, and 96.94% directly resulting from the action of the IL-6 receptor inhibitors. The findings preliminarily indicated that race constituted a variable potentially influencing the differential effects of IL-6 receptor inhibitors among patients with type 2 diabetes (T2D) across various regions. While the administration of IL-6 receptor inhibitors might impact glucose concentrations in CSF, the role of T2D as a mediator in CSF metabolites was weak. The predominant determinant appeared to be the administration of IL-6 receptor inhibitors.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000050063","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T18:01:22Z","timestamp":1786125682000},"page":"e50063","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Impact of IL-6 receptor inhibitors on cerebrospinal fluid metabolites in type 2 diabetes patients"],"prefix":"10.1097","volume":"105","author":[{"given":"Naidan","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine, Peoples Hospital of Deyang City, Deyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaixia","family":"Ji","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Peoples Hospital of Deyang City, Deyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Xin","sequence":"additional","affiliation":[{"name":"Department of Medical Technology, Chengdu University of Traditional Chinese Medicine, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baibing","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Medical Technology, Chengdu Medical College, Chengdu, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2187-3498","authenticated-orcid":false,"given":"Chengliang","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Peoples Hospital of Deyang City, Deyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260807","first-page":"699","article-title":"Hepatic insulin resistance and type 2 diabetes mellitus.","volume":"44","author":"Liu","year":"2022","journal-title":"Zhongguo Yi Xue Ke Xue Yuan Xue Bao"},{"key":"R2-20260807","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1016\/j.bbadis.2018.08.034","article-title":"Type 2 diabetes - An autoinflammatory disease driven by metabolic stress.","volume":"1864","author":"Gonzalez","year":"2018","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"R3-20260807","first-page":"610","article-title":"Receptor for advanced glycation end products involved in circulating endothelial cells release from human coronary endothelial cells induced by C-reactive protein.","volume":"18","author":"Zhou","year":"2015","journal-title":"Iran J Basic Med Sci"},{"key":"R4-20260807","first-page":"111","article-title":"C-reactive protein and diabetic retinopathy in Chinese patients with type 2 diabetes mellitus.","volume":"9","author":"Yang","year":"2016","journal-title":"Int J Ophthalmol"},{"key":"R5-20260807","doi-asserted-by":"crossref","first-page":"3920","DOI":"10.1158\/0008-5472.CAN-19-3685","article-title":"IL6 fuels durable memory for Th17 cell-mediated responses to tumors.","volume":"80","author":"Knochelmann","year":"2020","journal-title":"Cancer Res"},{"key":"R6-20260807","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1515\/cmble-2015-0004","article-title":"Single nucleotide polymorphisms in the STAT3 gene influence AITD susceptibility, thyroid autoantibody levels, and IL6 and IL17 secretion.","volume":"20","author":"Kotkowska","year":"2015","journal-title":"Cell Mol Biol Lett"},{"key":"R7-20260807","doi-asserted-by":"crossref","first-page":"112786","DOI":"10.1016\/j.intimp.2024.112786","article-title":"The effects of immunomodulatory drugs on cerebral small vessel disease: a mediation Mendelian randomization analysis.","volume":"140","author":"Lv","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"R8-20260807","doi-asserted-by":"crossref","first-page":"104118","DOI":"10.1016\/j.isci.2022.104118","article-title":"Regulation of Il6 expression by single CpG methylation in downstream of Il6 transcription initiation site.","volume":"25","author":"Lian","year":"2022","journal-title":"iScience"},{"key":"R9-20260807","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.jped.2020.11.004","article-title":"The critical function of miR-1323\/Il6 axis in children with mycoplasma pneumoniae pneumonia.","volume":"97","author":"Yin","year":"2021","journal-title":"J Pediatr (Rio J)"},{"key":"R10-20260807","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1620\/tjem.251.9","article-title":"Subcutaneous tocilizumab is effective for treatment of elderly-onset rheumatoid arthritis.","volume":"251","author":"Kondo","year":"2020","journal-title":"Tohoku J Exp Med"},{"key":"R11-20260807","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1016\/j.reuma.2011.01.001","article-title":"Tocilizumab in rheumatoid arthritis.","volume":"6S3","author":"Gotor","year":"2011","journal-title":"Reumatol Clin"},{"key":"R12-20260807","doi-asserted-by":"crossref","first-page":"447","DOI":"10.2217\/imt-2017-0173","article-title":"Tocilizumab in the treatment of adult rheumatoid arthritis.","volume":"10","author":"Sanmarti","year":"2018","journal-title":"Immunotherapy"},{"key":"R13-20260807","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13098-023-01252-1","article-title":"Lipid-lowering drugs and inflammatory bowel disease\u2019s risk: a drug-target Mendelian randomization study.","volume":"16","author":"Zhao","year":"2024","journal-title":"Diabetol Metab Syndr"},{"key":"R14-20260807","doi-asserted-by":"crossref","first-page":"e0293960","DOI":"10.1371\/journal.pone.0293960","article-title":"Association of lipid-lowering drugs with osteoarthritis outcomes from a drug-target Mendelian randomization study.","volume":"19","author":"Ma","year":"2024","journal-title":"PLoS One"},{"key":"R15-20260807","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1038\/s41467-022-29650-5","article-title":"Genetic analysis of over half a million people characterises C-reactive protein loci.","volume":"13","author":"Said","year":"2022","journal-title":"Nat Commun"},{"key":"R16-20260807","doi-asserted-by":"crossref","first-page":"739592","DOI":"10.3389\/fimmu.2021.739592","article-title":"Tocilizumab (TCZ) decreases angiogenesis in rheumatoid arthritis through its regulatory effect on miR-146a-5p and EMMPRIN\/CD147.","volume":"12","author":"Zisman","year":"2021","journal-title":"Front Immunol"},{"key":"R17-20260807","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.dadm.2017.11.007","article-title":"The wisconsin registry for alzheimer\u2019s prevention: a review of findings and current directions.","volume":"10","author":"Johnson","year":"2018","journal-title":"Alzheimers Dement (Amst)"},{"key":"R18-20260807","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/gepi.22211","article-title":"Integrated analysis of genomics, longitudinal metabolomics, and Alzheimer\u2019s risk factors among 1,111 cohort participants.","volume":"43","author":"Darst","year":"2019","journal-title":"Genet Epidemiol"},{"key":"R19-20260807","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s42003-020-01583-z","article-title":"Cerebrospinal fluid metabolomics identifies 19 brain-related phenotype associations.","volume":"4","author":"Panyard","year":"2021","journal-title":"Commun Biol"},{"key":"R20-20260807","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.3390\/nu14091878","article-title":"Body Mass Index and the risk of atrial fibrillation: a mendelian randomization study.","volume":"14","author":"Ma","year":"2022","journal-title":"Nutrients"},{"key":"R21-20260807","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s43586-021-00092-5","article-title":"Mendelian randomization.","volume":"2","author":"Sanderson","year":"2022","journal-title":"Nat Rev Methods Primers"},{"key":"R22-20260807","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s10654-017-0255-x","article-title":"Interpreting findings from Mendelian randomization using the MR-Egger method.","volume":"32","author":"Burgess","year":"2017","journal-title":"Eur J Epidemiol"},{"key":"R23-20260807","doi-asserted-by":"crossref","first-page":"e000256","DOI":"10.1136\/rmdopen-2016-000256","article-title":"From patients with arthralgia, pre-RA and recently diagnosed RA: what is the current status of understanding RA pathogenesis?","volume":"4","author":"Molendijk","year":"2018","journal-title":"RMD Open"},{"key":"R24-20260807","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.diabet.2011.11.006","article-title":"Inflammation and type 2 diabetes.","volume":"38","author":"Calle","year":"2012","journal-title":"Diabetes Metab"},{"key":"R25-20260807","doi-asserted-by":"crossref","first-page":"101563","DOI":"10.1016\/j.redox.2020.101563","article-title":"Relationship between PMN-endothelium interactions, ROS production and Beclin-1 in type 2 diabetes.","volume":"34","author":"De Maranon","year":"2020","journal-title":"Redox Biol"},{"key":"R26-20260807","doi-asserted-by":"crossref","first-page":"109138","DOI":"10.1016\/j.biopha.2019.109138","article-title":"Research progress in the relationship between type 2 diabetes mellitus and intestinal flora.","volume":"117","author":"Ma","year":"2019","journal-title":"Biomed Pharmacother"},{"key":"R27-20260807","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.cyto.2018.12.012","article-title":"Palmitate-induced IL6 expression ameliorated by chicoric acid through AMPK and SIRT1-mediated pathway in the PBMCs of newly diagnosed type 2 diabetes patients and healthy subjects.","volume":"116","author":"Sadeghabadi","year":"2019","journal-title":"Cytokine"},{"key":"R28-20260807","doi-asserted-by":"crossref","first-page":"7529779","DOI":"10.1155\/2024\/7529779","article-title":"The concentrations of interleukin-6, insulin, and glucagon in the context of obesity and type 2 diabetes and single nucleotide polymorphisms in IL6 and INS Genes.","volume":"2024","author":"Krol-Kulikowska","year":"2024","journal-title":"J Obes"},{"key":"R29-20260807","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1515\/hmbci-2022-0103","article-title":"Plasma IL-6, TREM1, uPAR, and IL6\/IL8 biomarkers increment further witnessing the chronic inflammation in type 2 diabetes.","volume":"44","author":"Sater","year":"2023","journal-title":"Horm Mol Biol Clin Investig"},{"key":"R30-20260807","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.15252\/embj.201488856","article-title":"The good, the bad, and the ugly of interleukin-6 signaling.","volume":"33","author":"Fuster","year":"2014","journal-title":"EMBO J"},{"key":"R31-20260807","doi-asserted-by":"crossref","first-page":"45777","DOI":"10.1074\/jbc.M301977200","article-title":"Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects.","volume":"278","author":"Rotter","year":"2003","journal-title":"J Biol Chem"},{"key":"R32-20260807","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.2337\/db05-1404","article-title":"Interleukin-6 increases insulin-stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via AMP-activated protein kinase.","volume":"55","author":"Carey","year":"2006","journal-title":"Diabetes"},{"key":"R33-20260807","doi-asserted-by":"crossref","first-page":"18138","DOI":"10.1074\/jbc.M000379200","article-title":"Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation.","volume":"275","author":"Terry","year":"2000","journal-title":"J Biol Chem"},{"key":"R34-20260807","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.cyto.2015.12.004","article-title":"Effect of G(-174)C polymorphism in interleukin-6 gene on cardiovascular disease in type 2 diabetes patients.","volume":"79","author":"Buraczynska","year":"2016","journal-title":"Cytokine"},{"key":"R35-20260807","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s00125-004-1623-0","article-title":"Variations of the interleukin-6 promoter are associated with features of the metabolic syndrome in Caucasian Danes.","volume":"48","author":"Hamid","year":"2005","journal-title":"Diabetologia"},{"key":"R36-20260807","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1210\/jc.2004-1606","article-title":"Molecular screening and association analyses of the interleukin 6 receptor gene variants with type 2 diabetes, diabetic nephropathy, and insulin sensitivity.","volume":"90","author":"Wang","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"R37-20260807","doi-asserted-by":"crossref","first-page":"4586","DOI":"10.1002\/1873-3468.12485","article-title":"AS-IL6 promotes glioma cell invasion by inducing H3K27Ac enrichment at the IL6 promoter and activating IL6 transcription.","volume":"590","author":"Wang","year":"2016","journal-title":"FEBS Lett"},{"key":"R38-20260807","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12964-017-0210-1","article-title":"NFAT1-regulated IL6 signalling contributes to aggressive phenotypes of glioma.","volume":"15","author":"Jiang","year":"2017","journal-title":"Cell Commun Signal"},{"key":"R39-20260807","doi-asserted-by":"crossref","first-page":"e01124","DOI":"10.1016\/j.heliyon.2019.e01124","article-title":"IL6\/IL6R genetic diversity and plasma IL6 levels in bipolar disorder: an Indo-French study.","volume":"5","author":"Sundaresh","year":"2019","journal-title":"Heliyon"},{"key":"R40-20260807","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.nbd.2016.01.015","article-title":"An altered peripheral IL6 response in major depressive disorder.","volume":"89","author":"Money","year":"2016","journal-title":"Neurobiol Dis"},{"key":"R41-20260807","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1093\/ijnp\/pyaa055","article-title":"Pro- and anti-inflammatory properties of interleukin (IL6) in vitro: relevance for major depression and for human hippocampal neurogenesis.","volume":"23","author":"Borsini","year":"2020","journal-title":"Int J Neuropsychopharmacol"},{"key":"R42-20260807","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1002\/mds.29122","article-title":"The impact of type 2 diabetes in parkinson\u2019s disease.","volume":"37","author":"Athauda","year":"2022","journal-title":"Mov Disord"},{"key":"R43-20260807","first-page":"4951379","article-title":"Analysis of the relationship between Type II diabetes mellitus and parkinson\u2019s disease: a systematic review.","volume":"2019","author":"Camargo Maluf","year":"2019","journal-title":"Parkinsons Dis"},{"key":"R44-20260807","doi-asserted-by":"crossref","first-page":"36270","DOI":"10.1038\/srep36270","article-title":"Determinants of high fasting insulin and insulin resistance among overweight\/obese adolescents.","volume":"6","author":"Ling","year":"2016","journal-title":"Sci Rep"},{"key":"R45-20260807","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/ijo.2015.125","article-title":"Insulin resistance in obesity can be reliably identified from fasting plasma insulin.","volume":"39","author":"ter Horst","year":"2015","journal-title":"Int J Obes (Lond)"},{"key":"R46-20260807","doi-asserted-by":"crossref","first-page":"778","DOI":"10.2337\/db12-0073","article-title":"Insulin resistance and type 2 diabetes.","volume":"61","author":"Taylor","year":"2012","journal-title":"Diabetes"},{"key":"R47-20260807","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1681\/ASN.2006010066","article-title":"IL-6 promoter polymorphism -174 is associated with new-onset diabetes after transplantation.","volume":"17","author":"Bamoulid","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"R48-20260807","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s12902-021-00738-1","article-title":"Association of IL-10 (- 1082 A\/G) and IL-6 (- 174 G\/C) gene polymorphism with type 2 diabetes mellitus in Ethiopia population.","volume":"21","author":"Ayelign","year":"2021","journal-title":"BMC Endocr Disord"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050063","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T20:02:18Z","timestamp":1786132938000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,7]]},"references-count":48,"journal-issue":{"issue":"32","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000050063","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,7]]},"assertion":[{"value":"2025-01-15","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-21","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}